eif4a3

eIF4A3-IN-1 is a selective and potent inhibitor of eukaryotic initiation factor 4A3 (eIF4A3) with an IC50 value of 0.26 μM. eIF4A3-IN-1 inhibits cytosolic nonsense-mediated RNA decay at high concentrations.

eIF4A3-IN-2 is a highly selective and noncompetitive inhibitor of eukaryotic initiation factor 4A-3, exhibiting an IC50 of 110 nM.

eIF4A3-IN-5 is a highly effective inhibitor of eukaryotic initiation factor 4A (eIF4A), specifically targeting eIF4AI and eIF4AII. With its potent inhibitory properties, eIF4A3-IN-5 shows great potential for advancing research in eIF4A-dependent diseases, including cancer studies.

eIF4A3-IN-7 is a highly effective inhibitor of eIF4A3, exhibiting significant potential for research in cancer and dysproliferative diseases.

eIF4A3-IN-4 is a novel inhibitor of eIF4A with an IC50 of 8.6 μM.

eIF4A3-IN-6 is a potent inhibitor of eukaryotic initiation factor 4A (eIF4A) [e.g., eIF4AI and eIF4AII] with potential for investigation in eIF4A-dependent diseases, including cancer.

(R)-eIF4A3-IN-2, a less active enantiomer of eIF4A3-IN-2, is a highly selective and noncompetitive inhibitor of the eukaryotic initiation factor 4A-3 (eIF4A3) with an IC50 of 110 nM.

eIF4A3-IN-17, a silvestrol analogue, disrupts the assembly of the eIF4F translation complex, exhibiting EC50 values of 0.9, 15, and 1.8 nM for myc-LUC, tub-LUC, and growth inhibition of MBA-MB-231 cells, respectively. This compound holds potential for research in human cancer pathogenesis [1].

eIF4A3-IN-18, a silvestrol analogue, disrupts the formation of the eIF4F translation complex, exhibiting EC 50 values of 0.8, 35, and 2 nM for myc-LUC, tub-LUC, and the growth inhibition of MBA-MB-231 cells, respectively. Additionally, it demonstrates cytotoxicity towards RMPI-8226 cells with an LC 50 of 0.06 nM. This compound is utilized in researching human cancer pathogenesis [1].

eIF4A3-IN-9, a silvestrol analogue, disrupts the assembly of the eIF4F translation complex, exhibiting EC50 values of 29, 450, and 80 nM for myc-LUC, tub-LUC, and growth inhibition in MBA-MB-231 cells, respectively. It is utilized in researching human cancer pathogenesis [1].